Metabolic syndrome and serum liver enzymes in the general chinese population

International Journal of Environmental Research and Public Health

Volumn 13, Issue 2, 2016, Pages

  Chen, Shuang ^a   Guo, Xiaofan ^a   Yu, Shasha ^a   Zhou, Ying ^a   Li, Zhao ^a   Sun, Yingxian ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; Liver enzymes; Metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; DISEASE PREVALENCE; ENZYME; METABOLISM; NUMERICAL MODEL; REGRESSION ANALYSIS; SERUM;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MORBIDITY; PREVALENCE; REFERENCE VALUE; RURAL AREA; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHINA; CLINICAL TRIAL; ENZYMOLOGY; LIVER; MULTICENTER STUDY; ODDS RATIO; RURAL POPULATION; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

CHINA;

ADULT; ALANINE TRANSAMINASE; ASIAN CONTINENTAL ANCESTRY GROUP; ASPARTATE AMINOTRANSFERASES; CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIVER; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PREVALENCE; REFERENCE VALUES; RURAL POPULATION;

EID: 84958811494     PISSN: 16617827     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph13020223     Document Type: Article

References (42)

1. Alberti, K.G.; Zimmet, P.; Shaw, J. The metabolic syndrome-A new worldwide definition. Lancet (Lond. Engl.) 2005, 366, 1059-1062. [CrossRef].
2. Lorenzo, C.; Okoloise, M.;Williams, K.; Stern, M.P.; Haffner, S.M. The metabolic syndrome as predictor of type 2 diabetes: The San Antonio heart study. Diabetes Care 2003, 26, 3153-3159. [CrossRef] [PubMed].
3. Sattar, N.; Gaw, A.; Scherbakova, O.; Ford, I.; O'Reilly, D.S.; Haffner, S.M.; Isles, C.; Macfarlane, P.W.; Packard, C.J.; Cobbe, S.M.; et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in theWest of Scotland Coronary Prevention Study. Circulation 2003, 108, 414-419. [CrossRef] [PubMed].
4. McNeill, A.M.; Rosamond, W.D.; Girman, C.J.; Golden, S.H.; Schmidt, M.I.; East, H.E.; Ballantyne, C.M.; Heiss, G. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005, 28, 385-390. [CrossRef] [PubMed].
5. Higashiyama, A.; Okamura, T.; Ono, Y.; Watanabe, M.; Kokubo, Y.; Okayama, A. Risk of smoking and metabolic syndrome for incidence of cardiovascular disease comparison of relative contribution in urban Japanese population: The Suita study. Circ. J. 2009, 73, 2258-2263. [CrossRef] [PubMed].
6. Hanley, A.J.; Williams, K.; Festa, A.; Wagenknecht, L.E.; D'Agostino, R.B., Jr.; Kempf, J.; Zinman, B.; Haffner, S.M. Elevations in markers of liver injury and risk of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes 2004, 53, 2623-2632. [CrossRef] [PubMed].
7. Lee, D.H.; Silventoinen, K.; Jacobs, D.R., Jr.; Jousilahti, P.; Tuomileto, J. -Glutamyltransferase, obesity, and the risk of type 2 diabetes: Observational cohort study among 20,158 middle-aged men and women. J. Clin. Endocrinol. Metab. 2004, 89, 5410-5414. [CrossRef] [PubMed].
8. Westerbacka, J.; Corner, A.; Tiikkainen, M.; Tamminen, M.; Vehkavaara, S.; Hakkinen, A.M.; Fredriksson, J.; Yki-Jarvinen, H. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: Implications for sex differences in markers of cardiovascular risk. Diabetologia 2004, 47, 1360-1369. [CrossRef] [PubMed].
9. Schindhelm, R.K.; Diamant, M.; Dekker, J.M.; Tushuizen, M.E.; Teerlink, T.; Heine, R.J. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab. Rese. Rev. 2006, 22, 437-443. [CrossRef] [PubMed].
10. Angelico, F.; del Ben, M.; Conti, R.; Francioso, S.; Feole, K.; Maccioni, D.; Antonini, T.M.; Alessandri, C. Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases. J. Gastroenterol. Hepatol. 2003, 18, 588-594. [CrossRef] [PubMed].
11. Cortez-Pinto, H.; Camilo, M.E.; Baptista, A.; de Oliveira, A.G.; de Moura, M.C. Non-alcoholic fatty liver: Another feature of the metabolic syndrome? Clin. Nutr. (Edinb. Scotl.) 1999, 18, 353-358. [CrossRef].
12. Marceau, P.; Biron, S.; Hould, F.S.; Marceau, S.; Simard, S.; Thung, S.N.; Kral, J.G. Liver pathology and the metabolic syndrome X in severe obesity. J. Clin. Endocrinol. Metab. 1999, 84, 1513-1517. [CrossRef] [PubMed].
13. Pagano, G.; Pacini, G.; Musso, G.; Gambino, R.; Mecca, F.; Depetris, N.; Cassader, M.; David, E.; Cavallo-Perin, P.; Rizzetto, M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology (Baltim. Md.) 2002, 35, 367-372. [CrossRef] [PubMed].
14. Marchesini, G.; Forlani, G. NASH: From liver diseases to metabolic disorders and back to clinical hepatology. Hepatology (Baltim. Md.) 2002, 35, 497-499. [CrossRef] [PubMed].
15. Oh, S.Y.; Cho, Y.K.; Kang, M.S.; Yoo, T.W.; Park, J.H.; Kim, H.J.; Park, D.I.; Sohn, C.I.; Jeon,W.K.; Kim, B.I.; et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 2006, 55, 1604-1609. [CrossRef] [PubMed].
16. Jeong, S.K.; Nam, H.S.; Rhee, J.A.; Shin, J.H.; Kim, J.M.; Cho, K.H. Metabolic syndrome and ALT: A community study in adult Koreans. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 1033-1038. [CrossRef] [PubMed].
17. Hanley, A.J.;Williams, K.; Festa, A.;Wagenknecht, L.E.; D'Agostino, R.B., Jr.; Haffner, S.M. Liver markers and development of the metabolic syndrome: The insulin resistance atherosclerosis study. Diabetes 2005, 54, 3140-3147. [CrossRef] [PubMed].
18. Prati, D.; Taioli, E.; Zanella, A.; della Torre, E.; Butelli, S.; del Vecchio, E.; Vianello, L.; Zanuso, F.; Mozzi, F.; Milani, S.; et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002, 137, 1-10. [CrossRef] [PubMed].
19. Mofrad, P.; Contos, M.J.; Haque, M.; Sargeant, C.; Fisher, R.A.; Luketic, V.A.; Sterling, R.K.; Shiffman, M.L.; Stravitz, R.T.; Sanyal, A.J. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (Baltim. Md.) 2003, 37, 1286-1292. [CrossRef] [PubMed].
20. Kim, H.C.; Nam, C.M.; Jee, S.H.; Han, K.H.; Oh, D.K.; Suh, I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. BMJ (Clin. Res. Ed.) 2004, 328, 983. [CrossRef] [PubMed].
21. O'Brien, E.; Petrie, J.; Littler,W.; de Swiet, M.; Padfield, P.L.; Altman, D.G.; Bland, M.; Coats, A.; Atkins, N. An outline of the revised British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J. Hypertens. 1993, 11, 677-679. [CrossRef] [PubMed].
22. Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.; Loria, C.M.; Smith, S.C., Jr.; et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120, 1640-1645. [PubMed].
23. Meisinger, C.; Doring, A.; Schneider, A.; Lowel, H. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis 2006, 189, 297-302. [CrossRef] [PubMed].
24. Lee, D.S.; Evans, J.C.; Robins, S.J.; Wilson, P.W.; Albano, I.; Fox, C.S.; Wang, T.J.; Benjamin, E.J.; D'Agostino, R.B.; Vasan, R.S. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: The Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 127-133. [CrossRef] [PubMed].
25. Schindhelm, R.K.; Dekker, J.M.; Nijpels, G.; Bouter, L.M.; Stehouwer, C.D.; Heine, R.J.; Diamant, M. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study. Atherosclerosis 2007, 191, 391-396. [CrossRef] [PubMed].
26. Wannamethee, S.G.; Shaper, A.G.; Lennon, L.; Whincup, P.H. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005, 28, 2913-2918. [CrossRef] [PubMed].
27. Marchesini, G.; Avagnina, S.; Barantani, E.G.; Ciccarone, A.M.; Corica, F.; Dall'Aglio, E.; Dalle Grave, R.; Morpurgo, P.S.; Tomasi, F.; Vitacolonna, E. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J. Endocrinol. Investig. 2005, 28, 333-339. [CrossRef].
28. Choi, K.M.; Lee, K.W.; Kim, H.Y.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Choi, D.S.; Baik, S.H. Association among serum ferritin, alanine aminotransferase levels, and metabolic syndrome in Korean postmenopausal women. Metabolism 2005, 54, 1510-1514. [CrossRef] [PubMed].
29. Park, H.S.; Han, J.H.; Choi, K.M.; Kim, S.M. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am. J. Clin. Nutr. 2005, 82, 1046-1051. [PubMed].
30. Kim, H.C.; Choi, S.H.; Shin, H.W.; Cheong, J.Y.; Lee, K.W.; Lee, H.C.; Huh, K.B.; Kim, D.J. Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. World J. Gastroenterol. 2005, 11, 5314-5321. [CrossRef] [PubMed].
31. Wedemeyer, H.; Hofmann, W.P.; Lueth, S.; Malinski, P.; Thimme, R.; Tacke, F.; Wiegand, J. ALT screening for chronic liver diseases: Scrutinizing the evidence. Z. Gastroenterol. 2010, 48, 46-55. [CrossRef] [PubMed].
32. Matsubara, K.; Matsuzawa, Y.; Jiao, S.; Takama, T.; Kubo, M.; Tarui, S. Relationship between hypertriglyceridemia and uric acid production in primary gout. Metabolism 1989, 38, 698-701. [CrossRef].
33. Villegas, R.; Xiang, Y.B.; Elasy, T.; Cai, Q.; Xu,W.; Li, H.; Fazio, S.; Linton, M.F.; Raiford, D.; Zheng,W.; et al. Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men. Metab. Syndr. Relat. Disord. 2011, 9, 305-311. [CrossRef] [PubMed].
34. Tiikkainen, M.; Bergholm, R.; Vehkavaara, S.; Rissanen, A.; Hakkinen, A.M.; Tamminen, M.; Teramo, K.; Yki-Jarvinen, H. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003, 52, 701-707. [CrossRef] [PubMed].
35. Uemura, H.; Katsuura-Kamano, S.; Yamaguchi, M.; Sawachika, F.; Arisawa, K. Serum hepatic enzyme activity and alcohol drinking status in relation to the prevalence of metabolic syndrome in the general Japanese population. PLoS ONE 2014, 9, e95981. [CrossRef] [PubMed].
36. Oda, E.; Kawai, R.; Watanabe, K.; Sukumaran, V. Prevalence of metabolic syndrome increases with the increase in blood levels of gamma glutamyltransferase and alanine aminotransferase in Japanese men and women. Intern. Med. (Tokyo Jpn.) 2009, 48, 1343-1350. [CrossRef].
37. Oh, H.J.; Kim, T.H.; Sohn, Y.W.; Kim, Y.S.; Oh, Y.R.; Cho, E.Y.; Shim, S.Y.; Shin, S.R.; Han, A.L.; Yoon, S.J.; et al. Association of serum alanine aminotransferase and gamma-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease. Korean J. Hepatol. 2011, 17, 27-36. [CrossRef] [PubMed].
38. Clark, J.M.; Brancati, F.L.; Diehl, A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 2003, 98, 960-967. [CrossRef] [PubMed].
39. Daniel, S.; Ben-Menachem, T.; Vasudevan, G.; Ma, C.K.; Blumenkehl, M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am. J. Gastroenterol. 1999, 94, 3010-3014. [CrossRef] [PubMed].
40. Marchesini, G.; Brizi, M.; Bianchi, G.; Tomassetti, S.; Bugianesi, E.; Lenzi, M.; McCullough, A.J.; Natale, S.; Forlani, G.; Melchionda, N. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001, 50, 1844-1850. [CrossRef] [PubMed].
41. Angelico, F.; del Ben, M.; Conti, R.; Francioso, S.; Feole, K.; Fiorello, S.; Cavallo, M.G.; Zalunardo, B.; Lirussi, F.; Alessandri, C.; et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2005, 90, 1578-1582. [CrossRef] [PubMed].
42. Fan, J.G.; Saibara, T.; Chitturi, S.; Kim, B.I.; Sung, J.J.; Chutaputti, A. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J. Gastroenterol. Hepatol. 2007, 22, 794-800. [CrossRef] [PubMed].